Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344559 | 0.82 | ALDH1A1 (0.41) | ALDH1A1ALOX15TSHR | |
| SCHEMBL2549272 | 0.80 | ALDH1A1 (0.35) | CDK1ALDH1A1ALOX15TSHR | |
| SCHEMBL10043017 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL6474069 | 0.75 | CDK1 (0.35) | CDK1ALDH1A1ALOX15TSHRIDO1 | |
| SCHEMBL3691752 | 0.75 | TLR8 (0.44) | ALDH1A1TLR8LMNA | |
| SCHEMBL19754271 | 0.75 | IDO1 (0.41) | CDK1ALDH1A1ALOX15TSHRTLR8 | |
| SCHEMBL19984155 | 0.75 | PDE10A (0.38) | CDK1ALDH1A1ALOX15TSHRIDO1 | |
| SCHEMBL5925922 | 0.75 | TLR8 (0.32) | TLR8LMNA | |
| SCHEMBL11775855 | 0.73 | LMNA (0.52) | CDK1ALDH1A1ALOX15TSHRTLR8 | |
| SCHEMBL30696400 | 0.73 | LMNA (0.52) | CDK1ALDH1A1ALOX15TSHRTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-114751903-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| CN-114269746-A | Spiro aromatic ring compound, preparation and application thereof | 上海奕拓医药科技有限责任公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-111153901-B | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-01-25 | — | — | CN | disclosed |
| EP-3878853-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021018287-A1 | SPIROAROMATIC COMPOUND, PREPARATION AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| CN-111153901-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-107454898-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3283474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | CDK1 3407/4885ALDH1A1 1908/4885ALOX15 2033/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | CDK1 3407/4885ALDH1A1 1908/4885ALOX15 2033/4885 |
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | PTPN1, PTPN7, PTPN9 | CDK1 468/4885ALDH1A1 3157/4885ALOX15 3038/4885 |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | CDK1 468/4885ALDH1A1 3157/4885ALOX15 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.